PDS Biotechnology Reports 2025 Financial Results with Strategic Developments
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy PDSB?
Source: Yahoo Finance
- Financial Performance: PDS Biotechnology reported a net loss of $34.5 million for 2025, translating to a basic and diluted loss of $0.74 per share, indicating ongoing financial challenges despite a reduction from the previous year's loss of $37.6 million.
- R&D Expenses: The company incurred $19 million in research and development expenses in 2025, down from $22.6 million in 2024, reflecting the significant costs associated with advancing clinical trials, yet future spending trends remain a concern.
- Cash Position: As of December 31, 2025, PDSB's cash balance stood at $26.7 million, which may limit its financial flexibility moving forward, particularly as further investments in R&D are anticipated.
- Clinical Advancements: PDS Biotechnology has made significant progress with the amendment of the VERSATILE-003 trial, which is expected to lead to a more efficient path to accelerated approval, although uncertainties regarding the exact enrollment targets and sample size persist.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PDSB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PDSB
Wall Street analysts forecast PDSB stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.606
Low
3.00
Averages
9.00
High
15.00
Current: 0.606
Low
3.00
Averages
9.00
High
15.00
About PDSB
PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
PDS Biotechnology Reports 2025 Financial Results with Strategic Developments
- Financial Performance: PDS Biotechnology reported a net loss of $34.5 million for 2025, translating to a basic and diluted loss of $0.74 per share, indicating ongoing financial challenges despite a reduction from the previous year's loss of $37.6 million.
- R&D Expenses: The company incurred $19 million in research and development expenses in 2025, down from $22.6 million in 2024, reflecting the significant costs associated with advancing clinical trials, yet future spending trends remain a concern.
- Cash Position: As of December 31, 2025, PDSB's cash balance stood at $26.7 million, which may limit its financial flexibility moving forward, particularly as further investments in R&D are anticipated.
- Clinical Advancements: PDS Biotechnology has made significant progress with the amendment of the VERSATILE-003 trial, which is expected to lead to a more efficient path to accelerated approval, although uncertainties regarding the exact enrollment targets and sample size persist.
See More
PDS Biotechnology Corporation Q4 2025 Earnings Call Insights
- Significant Clinical Progress: PDS Biotechnology's Q4 2025 earnings report highlights that the amendment to the VERSATILE-003 protocol is expected to shorten trial duration and reduce costs, thereby accelerating regulatory submission while maintaining overall survival as the basis for approval, showcasing the company's innovative capabilities in clinical trial design.
- Decrease in R&D Expenses: Research and development expenses for 2025 were reported at $19 million, down from $22.6 million in 2024, primarily due to reductions in manufacturing and personnel costs, reflecting effective financial management while leaving room for future investments.
- Enhanced Intellectual Property Protection: The company secured new patents for PDS0101 in the U.S. and Japan, extending market protection into the 2040s, indicating that PDS Biotechnology's strategic positioning in intellectual property will support its long-term market potential.
- Optimistic Outlook: Although management did not provide specific financial guidance, they expressed optimism regarding the amendment of the VERSATILE-003 trial and future patient enrollment, which is expected to lead to a faster regulatory path and potential market opportunities.
See More
PDS Biotechnology Reports FY 2025 Financial Results
- Financial Performance: PDS Biotechnology reported a GAAP EPS of -$0.74 for FY 2025, indicating challenges in profitability that could impact investor confidence and exert downward pressure on stock prices.
- Cash Position: As of December 31, 2025, the company had a cash balance of $26.7 million, which, while providing some liquidity, raises concerns about capital efficiency and potential future financing needs.
- Market Reaction: The reported losses may lead to a cautious market outlook for PDS Biotechnology, prompting investors to closely monitor subsequent strategic adjustments and financial improvement initiatives.
- Future Outlook: The company must implement effective measures to enhance profitability in order to navigate market competition and achieve sustainable growth, particularly in the context of rapid advancements in the biotechnology sector.
See More
PDS Biotechnology Set to Release FY Earnings
- Earnings Announcement: PDS Biotechnology is set to announce its FY earnings on March 30th after market close, with investors keenly awaiting the results to gauge the company's future growth potential.
- EPS Expectations: The consensus EPS estimate stands at -$0.80, reflecting a 22.3% year-over-year improvement, indicating the company's efforts to enhance profitability despite still being in a loss position.
- Revenue Forecast: The consensus revenue estimate for PDS Biotechnology is $0, highlighting the challenges the company faces in revenue growth, which could impact investor confidence.
- Quant Rating Insight: Seeking Alpha's Quant Rating on PDS Biotechnology provides market analysis perspectives, aiding investors in better understanding the company's financial health and competitive position in the biotech sector.
See More
PDS Biotechnology Amends Phase 3 Trial Protocol for Accelerated Approval
- Protocol Amendment: PDS Biotechnology Corporation announced an amendment to its Phase 3 VERSATILE-003 clinical trial protocol, adding progression-free survival (PFS) as an interim primary endpoint to support a potential accelerated approval pathway for PDS0101 in HPV16-positive recurrent and/or metastatic head and neck cancer.
- Survival Endpoint Maintained: While PFS is added as an interim endpoint, the median overall survival (mOS) remains the primary endpoint, ensuring consistency with prior regulatory dialogues with the FDA, thereby enhancing the company's confidence in the regulatory approval process.
- Accelerated Approval Potential: By including PFS as an interim primary endpoint, the trial duration is expected to shorten, accelerating the timeline for regulatory submission while improving cost efficiency, further advancing the company's strategic positioning in cancer immunotherapy.
- Optimistic Market Outlook: PDS0101, as a targeted immunotherapy for HPV16-positive recurrent and/or metastatic head and neck cancer, developed in combination with standard immune checkpoint inhibitors, demonstrates strong market potential, aligning with the growing patient demand.
See More
Oncolytics Biotech Advances Pelareorep for Anal Cancer with 29% Response Rate
- Clinical Data Breakthrough: Oncolytics Biotech's pelareorep demonstrated a 29% objective response rate in anal cancer during the GOBLET Cohort 4, significantly exceeding the historical benchmark of 10%, indicating its crucial clinical value in a setting with no FDA-approved treatment options.
- Duration of Response: Among 14 evaluable patients, the median duration of response for pelareorep reached approximately 17 months, far surpassing the standard treatment's 9.5 months, showcasing the drug's durable efficacy in heavily pretreated patients and addressing a critical unmet medical need.
- FDA Accelerated Approval Plans: Oncolytics plans to hold a Type C meeting with the FDA in Q1 2026 to discuss advancing pelareorep into a registration-directed clinical study, paving the way for potential accelerated approval if the data is validated.
- Strategic Investment and Expert Support: The company expanded its Scientific Advisory Board by adding three globally recognized experts from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center, further strengthening its strategic positioning in the gastrointestinal oncology field.
See More
PDS Biotechnology Reports 2025 Financial Results with Strategic Developments
- Financial Performance: PDS Biotechnology reported a net loss of $34.5 million for 2025, translating to a basic and diluted loss of $0.74 per share, indicating ongoing financial challenges despite a reduction from the previous year's loss of $37.6 million.
- R&D Expenses: The company incurred $19 million in research and development expenses in 2025, down from $22.6 million in 2024, reflecting the significant costs associated with advancing clinical trials, yet future spending trends remain a concern.
- Cash Position: As of December 31, 2025, PDSB's cash balance stood at $26.7 million, which may limit its financial flexibility moving forward, particularly as further investments in R&D are anticipated.
- Clinical Advancements: PDS Biotechnology has made significant progress with the amendment of the VERSATILE-003 trial, which is expected to lead to a more efficient path to accelerated approval, although uncertainties regarding the exact enrollment targets and sample size persist.
See More
PDS Biotechnology Corporation Q4 2025 Earnings Call Insights
- Significant Clinical Progress: PDS Biotechnology's Q4 2025 earnings report highlights that the amendment to the VERSATILE-003 protocol is expected to shorten trial duration and reduce costs, thereby accelerating regulatory submission while maintaining overall survival as the basis for approval, showcasing the company's innovative capabilities in clinical trial design.
- Decrease in R&D Expenses: Research and development expenses for 2025 were reported at $19 million, down from $22.6 million in 2024, primarily due to reductions in manufacturing and personnel costs, reflecting effective financial management while leaving room for future investments.
- Enhanced Intellectual Property Protection: The company secured new patents for PDS0101 in the U.S. and Japan, extending market protection into the 2040s, indicating that PDS Biotechnology's strategic positioning in intellectual property will support its long-term market potential.
- Optimistic Outlook: Although management did not provide specific financial guidance, they expressed optimism regarding the amendment of the VERSATILE-003 trial and future patient enrollment, which is expected to lead to a faster regulatory path and potential market opportunities.
See More
PDS Biotechnology Reports FY 2025 Financial Results
- Financial Performance: PDS Biotechnology reported a GAAP EPS of -$0.74 for FY 2025, indicating challenges in profitability that could impact investor confidence and exert downward pressure on stock prices.
- Cash Position: As of December 31, 2025, the company had a cash balance of $26.7 million, which, while providing some liquidity, raises concerns about capital efficiency and potential future financing needs.
- Market Reaction: The reported losses may lead to a cautious market outlook for PDS Biotechnology, prompting investors to closely monitor subsequent strategic adjustments and financial improvement initiatives.
- Future Outlook: The company must implement effective measures to enhance profitability in order to navigate market competition and achieve sustainable growth, particularly in the context of rapid advancements in the biotechnology sector.
See More
PDS Biotechnology Set to Release FY Earnings
- Earnings Announcement: PDS Biotechnology is set to announce its FY earnings on March 30th after market close, with investors keenly awaiting the results to gauge the company's future growth potential.
- EPS Expectations: The consensus EPS estimate stands at -$0.80, reflecting a 22.3% year-over-year improvement, indicating the company's efforts to enhance profitability despite still being in a loss position.
- Revenue Forecast: The consensus revenue estimate for PDS Biotechnology is $0, highlighting the challenges the company faces in revenue growth, which could impact investor confidence.
- Quant Rating Insight: Seeking Alpha's Quant Rating on PDS Biotechnology provides market analysis perspectives, aiding investors in better understanding the company's financial health and competitive position in the biotech sector.
See More
PDS Biotechnology Amends Phase 3 Trial Protocol for Accelerated Approval
- Protocol Amendment: PDS Biotechnology Corporation announced an amendment to its Phase 3 VERSATILE-003 clinical trial protocol, adding progression-free survival (PFS) as an interim primary endpoint to support a potential accelerated approval pathway for PDS0101 in HPV16-positive recurrent and/or metastatic head and neck cancer.
- Survival Endpoint Maintained: While PFS is added as an interim endpoint, the median overall survival (mOS) remains the primary endpoint, ensuring consistency with prior regulatory dialogues with the FDA, thereby enhancing the company's confidence in the regulatory approval process.
- Accelerated Approval Potential: By including PFS as an interim primary endpoint, the trial duration is expected to shorten, accelerating the timeline for regulatory submission while improving cost efficiency, further advancing the company's strategic positioning in cancer immunotherapy.
- Optimistic Market Outlook: PDS0101, as a targeted immunotherapy for HPV16-positive recurrent and/or metastatic head and neck cancer, developed in combination with standard immune checkpoint inhibitors, demonstrates strong market potential, aligning with the growing patient demand.
See More
Oncolytics Biotech Advances Pelareorep for Anal Cancer with 29% Response Rate
- Clinical Data Breakthrough: Oncolytics Biotech's pelareorep demonstrated a 29% objective response rate in anal cancer during the GOBLET Cohort 4, significantly exceeding the historical benchmark of 10%, indicating its crucial clinical value in a setting with no FDA-approved treatment options.
- Duration of Response: Among 14 evaluable patients, the median duration of response for pelareorep reached approximately 17 months, far surpassing the standard treatment's 9.5 months, showcasing the drug's durable efficacy in heavily pretreated patients and addressing a critical unmet medical need.
- FDA Accelerated Approval Plans: Oncolytics plans to hold a Type C meeting with the FDA in Q1 2026 to discuss advancing pelareorep into a registration-directed clinical study, paving the way for potential accelerated approval if the data is validated.
- Strategic Investment and Expert Support: The company expanded its Scientific Advisory Board by adding three globally recognized experts from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center, further strengthening its strategic positioning in the gastrointestinal oncology field.
See More
